Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
November 03, 2022 09:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that results from the...
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
October 31, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
September 30, 2022 17:30 ET
|
Apellis Pharmaceuticals, Inc.
New analyses of microperimetry data showed positive trends with both monthly and every-other-month pegcetacoplan treatment near the GA lesion border compared to shamThese analyses provide further...
Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting
September 30, 2022 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that four oral...
Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
September 12, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
September 01, 2022 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
August 24, 2022 08:00 ET
|
Apellis Pharmaceuticals, Inc.
Pegcetacoplan treatment effect accelerated between months 18-24, demonstrating a robust reduction of GA lesion growth compared to sham (all p-values are nominal) DERBY: 36% monthly, p<0.0001; 29%...
Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 08, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
Received U.S. FDA filing acceptance of NDA with Priority Review designation for intravitreal pegcetacoplan for treatment of geographic atrophy; PDUFA target action date of November 26, 2022Achieved...